Antiretroviral treatment simplification with nevirapine in protease inhibitor - Experienced patients with HIV-associated lipodystrophy: 1-Year prospective follow-up of a multicenter, randomized, controlled study

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 3, 2001, Pages 229-236

  Ruiz, Lidia ^a   Negredo, Eugenia ^a   Domingo, Pere ^b   Paredes, Roger ^a,b   Francia, Esther ^b   Balagué, Montserrat ^a   Gel, Silvia ^a   Bonjoch, Anna ^a   Fumaz, Carmina R ^a   Johnston, Susan ^a   Romeu, Joan ^a   Lange, Joep ^c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

HIV; Lipodystrophy; Nevirapine; Protease inhibitors; Treatment simplification

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CHOLESTEROL; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ACUTE HEPATITIS; ADULT; ANEMIA; ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 0035393524     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200107010-00003     Document Type: Article

References (29)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
4. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
5. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
6. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
7. A prospective open label pilot trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months
8. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
9. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study
10. Cumulative risk for developing protease inhibitor-associated lipodystrophy
11. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
12. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
13. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
14. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
15. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study
16. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
17. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to HAART
18. Validation of body composition by dual x-ray absorptiometry (DEXA)
19. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: Enhanced sensitivity
20. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/microL CD4 T cells and undetectable plasma virus load
21. A health status questionnaire using 30 items from the medical outcomes study
22. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy
23. Management of antiretroviral therapy for HIV infection: Modeling when to change therapy
24. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitor (PI) to efavirenz
25. "Buffalo hump" in men with HIV infection
26. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
27. A randomized, controlled trial of intermittent versus continuous highly active antiretroviral therapy (HAART)
28. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy
29. Incidence and risk factors associated with the occurrence of severe hepatic cytolysis in the ICONA study